Institutional shares held 45.4 Million
64.9K calls
103K puts
Total value of holdings $395M
$564K calls
$896K puts
Market Cap $376M
43,230,000 Shares Out.
Institutional ownership 105.03%
# of Institutions 182


Latest Institutional Activity in RGNX

Top Purchases

Q2 2025
Wealth Enhancement Advisory Services, LLC Shares Held: 30.6K ($266K)
Q2 2025
Pallas Capital Advisors LLC Shares Held: 17.4K ($151K)
Q2 2025
Gamma Investing LLC Shares Held: 2.93K ($25.5K)
Q2 2025
Diversified Trust CO Shares Held: 10.8K ($93.6K)
Q2 2025
Uma Financial Services, Inc. Shares Held: 113 ($983)

Top Sells

Q2 2025
Janney Montgomery Scott LLC Shares Held: 57.6K ($501K)
Q2 2025
Versant Capital Management, Inc Shares Held: 224 ($1.95K)
Q2 2025
Assenagon Asset Management S.A. Shares Held: 572K ($4.98M)
Q2 2025
Signaturefd, LLC Shares Held: 2K ($17.4K)
Q1 2025
State Street Corp Shares Held: 1.07M ($9.28M)

About RGNX

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.


Insider Transactions at RGNX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
684K Shares
From 16 Insiders
Grant, award, or other acquisition 525K shares
Exercise of conversion of derivative security 159K shares
Sell / Disposition
171K Shares
From 7 Insiders
Open market or private sale 101K shares
Payment of exercise price or tax liability 69.9K shares

Track Institutional and Insider Activities on RGNX

Follow REGENXBIO Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RGNX shares.

Notify only if

Insider Trading

Get notified when an Regenxbio Inc. insider buys or sells RGNX shares.

Notify only if

News

Receive news related to REGENXBIO Inc.

Track Activities on RGNX